SPOTLIGHT: Acambis contract offers long-term funding


The announcement that Acambis has won a $425 million, 10-year contract to supply the U.S. government with its smallpox vaccine, along with a new share placement, will provide the company with enough cash to fund operations for the medium term. To win the contract, Acambis had to agree to produce the vaccine in the U.S. Report

Suggested Articles

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.

GlaxoSmithKline’s vaccines unit has been a bright spot for the company, but its performance doesn’t make it immune to staff cuts.